Lemon Balm and Lavender herbal essential oils: Old and new ways to treat emotional disorders?

Current Anaesthesia and Critical Care

Volumn 19, Issue 4, 2008, Pages 221-226

  Abuhamdah, Sawsan ^a,b   Chazot, Paul L ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Agitation; Anxiety; Lavender; Lemon Balm; Natural products

Indexed keywords

ALDEHYDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROPHYLLENE; CITRAL; CITRONELLAL; ESSENTIAL OIL; GERMACRENE D; GERNIOL; HERBACEOUS AGENT; LAVENDER OIL; MELISSA OFFICINALIS EXTRACT; NEROL; NEUROLEPTIC AGENT; OCIMENE; OLANZAPINE; PLACEBO; PLANT EXTRACT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SESQUITERPENE; TERPENE; TRIAZOLAM; UNINDEXED DRUG; VALERIAN;

AGGRESSION; AGITATION; ANXIETY DISORDER; AROMATHERAPY; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONSTIPATION; DEGENERATIVE DISEASE; DELIRIUM; DEMENTIA; DEPRESSION; DISTILLATION; DROWSINESS; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FALLING; HEART ARRHYTHMIA; HUMAN; MASSAGE; MONOTHERAPY; MORTALITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHYTOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; SEDATION; SIDE EFFECT; STROKE; TRADITIONAL MEDICINE; URINE RETENTION;

EID: 48749088913     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2008.05.005     Document Type: Article

References (60)

1. Jones W.P., Chin Y.W., and Kinghorn A.D. The role of pharmacognosy in modern medicine and pharmacy. Curr Drug Targets 7 3 (2006) 247-264
2. Diamond B., Johnson S., Torsney K., Morodan J., Prokop B., Davidek D., et al. Complementary and alternative medicines in the treatment of dementia: an evidence-based review. Drugs Aging 20 13 (2003) 981-998
3. Perry N., and Perry E. Aromatherapy in the management of psychiatric disorders: clinical and neuropharmacological perspectives. CNS Drugs 20 4 (2006) 257-280
4. Beaubrun G., and Gray G.E. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 51 9 (2000) 1130-1134
5. Howes M.J., Perry N.S., and Houghton P.J. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 17 1 (2003) 1-18
6. Sato S., Mizukami K., Moro K., Tanaka Y., and Asada T. Efficacy of perospirone in the management of aggressive behavior associated with dementia. Prog Neuropsychopharmacol Biol Psychiat 30 4 (2006) 679-683
7. Lanari A., Amenta F., Silvestrelli G., Tomassoni D., and Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 127 2 (2006) 158-165
8. Herrmann N., and Lanctôt K.L. From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Can J Psychiat 42 Suppl. 1 (1997) 51S-64S
9. Rojas-Fernandez C.H., Lanctot K.L., Allen D.D., and MacKnight C. Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?. Pharmacotherapy 21 1 (2001) 74-102
10. Carson S., McDonagh M.S., and Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatric Soc 54 2 (2006) 354-361 Erratum in: J Am Geriatric Soc 2006;54(9):1479 (September)
11. Brodaty H., Ames D., Snowdon J., Woodward M., Kirwan J., Clarnette R., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64 2 (2003) 134-143
12. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L., Eriksson S., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 5 (1999) 946-955
13. Schneider L.S. Pharmacologic management of psychosis in dementia. J Clin Psychiat 60 Suppl. 8 (1999) 54-60
14. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., and Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiat 60 2 (1999) 107-115
15. Gurvich T., and Cunningham J.A. Appropriate use of psychotropic drugs in nursing homes. Am Fam Physician 61 5 (2000) 1437-1446
16. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 167 11 (2002) 1269-1270
17. Smith D.A., and Beier M.T. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 5 2 (2004) 129-132
18. Percudani M., Barbui C., Fortino I., Tansella M., and Petrovich L. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 25 5 (2005) 468-470
19. Kurz A., Schwalen S S., and Schmitt A. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. Int Psychogeriatr 17 4 (2005) 605-616
20. Daiello L.A., Beier M.T., Hoffmann V.P., and Kennedy J.S. Pharmacotherapy of behavioral and psychological symptoms of dementia: a review of atypical antipsychotics. Consult Pharm 18 2 (2003) 138-152 155-7
21. Ballard C.G., O'Brien J.T., Reichelt K., and Perry E.K. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiat 63 7 (2002) 553-558
22. Kim E.J., and Buschmann M.T. The effect of expressive physical touch on patients with dementia. Int J Nurs Stud 36 3 (1999) 235-243
23. Vance D. Considering olfactory stimulation for adults with age-related dementia. Percept Mot Skills 88 2 (1999) 398-400
24. Perry E.K., Pickering A.T., Wang W.W., Houghton P.J., and Perry N.S. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol 51 5 (1999) 527-534
25. Perry E.K., Pickering A.T., Wang W.W., Houghton P., and Perry N.S. Medicinal plants and Alzheimer's disease: integrating ethnobotanical and contemporary scientific evidence. J Altern Complement Med 4 4 (1998) 419-428
26. Houghton P.J., and Seth P. Plants and the central nervous system. Pharmacol Biochem Behav 75 (2003) 497-499
27. Tisserand R. Lavender beats benzodiazepines. Int J Aromatherapy 1 (1988) 1-2
28. Newall C.A., Anderson L.A., and Pillipson J.D. Herbal medicine: a guide for healthcare professionals (1996), Pharmaceutical Press, London
29. Price S., and Price L. Aromatherapy for health professionals (1999), Churchill Livingstone Press, Edinburgh
30. Buckle J. Clinical aromatherapy essential oil practice (2003), Churchill Livingstone, New York
31. Garcia-Alloza M., Gil-Bea F.J., Diez-Ariza M., Chen C.P., Francis P.T., Lasheras B., et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43 3 (2005) 442-449
32. Eichelman B.S. Neurochemical and psychopharmacologic aspects of aggressive behavior. Annu Rev Med 41 (1990) 149-158
33. Garcia-Alloza M., Tsang S.W., Gil-Bea F.J., Francis P.T., Lai M.K., Marcos B., et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol Aging 27 8 (2006) 1110-1117
34. Lanctôt K.L., Herrmann N., Rothenburg L., and Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int Psychogeriatr 19 1 (2007) 151-158
35. Mellow A.M., Solano-Lopez C., and Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiat Neurol 6 4 (1993) 205-209
36. McVickar J. Jekka's complete herb book (1994), Kyle Cathie, London
37. Bisset N. Herbal drugs and phytopharmaceuticals (1994), MedPharm GMbH Scientific, Stuttgart
38. Tittel G., Wagner H., and Bos R. Chemical composition of the essential oil from Melissa. Planta Med 46 10 (1982) 91-98 (in German)
39. Yarnell E. Lemon balm. Alter Complement Ther 4 (1998) 417-419
40. Soulimani R., Fleurentin J., Mortier F., Misslin R., Derrieu G., and Pelt J.M. Neurotropic action of the hydroalcoholic extract of Melissa officinalis in the mouse. Planta Med 57 2 (1991) 105-109
41. Kennedy D.O., Wake G., Savelev S., Tildesley N.T., Perry E.K., Wesnes K.A., et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology 28 10 (2003) 1871-1881
42. Kennedy D.O., Little W., and Scholey A.B. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med 66 4 (2004) 607-613
43. Kennedy D.O., Scholey A.B., Tildesley N.T., Perry E.K., and Wesnes K.A. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav 72 4 (2002) 953-964
44. Wake G., Court J., Pickering A., Lewis R., Wilkins R., and Perry E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol 69 2 (2000) 105-114
45. Duke J. Hand book of medicinal herb (1989), CRC Press, Boca Raton, FL
46. Evans W. Trease and Evan's pharmacognosy (1989), Bailliere Tindall, London
47. Leung A., and Foster S. Encyclopaedia of common natural ingredients used in food, drugs and cosmetics. 2nd ed (1996), Wiley, New York p. 339-42
48. Wagner H., and Bladt S. Plant drug analysis: a thin layer chromatography atlas (1996), Springer, Berlin
49. Cavanagh H.M., and Wilkinson J.M. Biological activities of lavender essential oil. Phytother Res 16 4 (2002) 301-308
50. Betts T. Use of aromatherapy (with or without hypnosis) in the treatment of intractable epilepsy-a two-year follow-up study. Seizure 12 8 (2003) 534-538
51. Yamada K., Mimaki Y., and Sashida Y. Anticonvulsive effects of inhaling lavender oil vapour. Biol Pharm Bull 17 2 (1994) 359-360
52. Umezo T. Behavioural effects of plant-derived essential oils in the geller type conflict test in mice. Jpn J Pharmacol 83 (2000) 150-153
53. Silva Brum L.F., Emanuelli T., Souza D.O., and Elisabetsky E. Effects of linalool on glutamate release and uptake in mouse cortical synaptosomes. Neurochem Res 26 3 (2001) 191-194
54. Re L., Barocci S., Sonnino S., Mencarelli A., Vivani C., Paolucci G., et al. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res 42 2 (2000) 177-182
55. Lis-Balchin M., and Hart S. Studies on the mode of action of the essential oil of lavender (Lavandula angustifolia P. Miller). Phytother Res 13 6 (1999) 540-542
56. Elisabetsky E., Marschner J., and Souza D.O. Effects of Linalool on glutamatergic system in the rat cerebral cortex. Neurochem Res 20 4 (1995) 461-465
57. Elisabetsky E., Brum L.F., and Souza D.O. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine 6 2 (1999) 107-113
58. Ennaceur A., Michalikova S., van Rensburg R., and Chazot P.L. Are benzodiazepines really anxiolytic? Evidence from a 3D maze spatial navigation task. Behav Brain Res 188 1 (2008) 136-153
59. Ennaceur A., Michalikova S., van Rensburg R., and Chazot P.L. Models of anxiety: responses of mice to novelty and open spaces in a 3D maze. Behav Brain Res 174 1 (2006) 9-38
60. Abuhamdah S., Huang L., Elliott M.S., Howes M.J., Ballard C., Holmes C., et al. Pharmacological profile of an essential oil derived from Melissa officinalis with anti-agitation properties: focus on ligand-gated channels. J Pharm Pharmacol 60 3 (2008) 377-384